Posters

36 Rapid Accumulation and Internalization of Radiolabeled HerceptinTM in a Inflammatory Breast Cancer Xenograft with Vasculogenic Mimicry Predicted by the Contrast-Enhanced Dynamic MRI with the Macromolecular Contrast Agent G6- (1B4M-Gd)256
Kobayashi, Hisataka¹ ; Shirakawa, Kazuo³ ; Kawamoto, Satomi¹ ; Saga, Tsuneo² ; Hiraga, Akira² ; Togashi, Kaori¹ ; Konishi, Junji² ; Brechbiel, Martin4; Wakasugi, Hiro³
¹Department; of Diagn. Intervent. Imagiology, Kyoto University, Kyoto, Japan; ²Department; of Nuclear Medicine and Diagn. Imaging, Kyoto University, Kyoto, Japan; ³Pharmacology; Division, National Cancer Center Research Institute, Tokyo, Japan; 4Radiation Oncology Branch, National Cancer Institute, Bethesda, MD
37 Effects of transforming growth factor – ß on the ability of dendritic cells to stimulate an anti-tumor response
Kobie JJ, Akporiaye ET
Department of Microbiology and Immunology, University of Arizona, Tucson, AZ
38 Enhancement of NK-mediated anti-tumor effects against allogeneic tumor by inhibitory receptor blockade
Koh, Crystal¹ Blazar, Bruce² Bennett, Michael³ Murphy, William4
¹Laboratory; of Molecular Immunoregulation, National Cancer Institute – Frederick, Frederick, MD; ²Dept; of Pediatrics,
Div of BMT, University of Minnesota Cancer Center, Minneapolis, MN; ³Dept; of Pathology, Univ of Texas Southwestern Medical Center Dallas, TX; 4IRSP, SAIC – Frederick, Frederick, MD
39 Reactivity of anti-Her-2/neu CTL against modified Her-2/neu peptides
Lake DF, Dionne SO, Smith, MH
Cancer Center, University of Arizona, Tucson, AZ
40 Vaccination of a prostate cancer patient with the candidate cancer vaccine IGN101: A case study
Samonigg H1, Hofmann G¹, Gusel S¹, Hopfner M², Putz T², Himmler G², Loibner H²
¹Dept.; Oncol. University Hospital, Graz; Austria; ²igeneon; AG, Vienna; Austria
41 Enhancing antitumor (anti-oncotope) antibody (IgM) promotes tumor growth in the syngeneic host
Manson, LA, Snyder, AK
Dept. Biology, University of Pennsylvania, Philadelphia, PA
42 Evaluation of the interleukin-2 selective agonist BAY-50-4798 in patients with advance melanoma and renal cell carcinoma, a Cytokine Working Group-coordinated phase I study
Margolin, K¹ Atkins, M B² Weber, J³ Dutcher, JP4; Ernstoff, M5; Smith, J6; Clark, J7; O’Day, S8; Flaherty, L9; Baar, J10; Sosman, J11; Thompson, JA12; Smith, J13; Lathia, C13; Martell, RE13¹City; of Hope, Duarte, CA; ²Beth; Israel Deaconess, Boston, MA; ³USC;, Los Angeles, CA ; 4Our Lady of Mercy, Bronx, NY; 5Dartmouth Lebanon, NH; 6Providence, Portland, OR; 7Loyola Maywood, IL; 8John Wayne, Santa Monica, CA; 9Wayne State Detroit, MI; 10U Pittsburgh, Pittsburgh, PA; 11U Illinois, Chicago, IL; 12U Washington, Seattle, WA; 13Bayer Pharmaceuticals West Haven, CT
43 Modulation of anti-tumor responses in mice by Albuleukin, an Interleukin-2 / human serum albumin fusion protein
Melder RJ, Grzegorzewski K, Osborn B, Riccobene T, Beebe L, Wei P, Zhang G, Chen G, Stolow D, Migone T, Kanakaraj P, Ruben S.
Human Genome Sciences, Rockville, MD
44 Endogenous Immune Responses Control Minimal Residual Neoplastic Disease in Murine Osteosarcoma
Fraia Melchionda, Manoj Sinha, Chand Khanna, Melinda Merchant, Terry Fry, Lee Helman and Crystal Mackall
Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD
45 Oral (1→3), (1→4) →D-glucan synergizes with the antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma
Modak, Shakeel; Cheung, Nai-Kong
Pediatrics, Memorial Sloan-Kettering Cancer Center
46 Efficiency of Adenoviral Mediated Gene Transfer into Murine Bone Marrow-Derived Dendritic Cells
Morrison B, Sakai Y, Janik JE, van den Broeke L, Berzofsky JA, Morris JC
Metabolism Branch, Center for Cancer Research, NCI, Bethesda, MD